Global Exocrine Pancreatic Insufficiency Market Report 2024: Market Size, CAGR, Lucrative Segments And Top Regions

Overview and Scope
Exocrine pancreatic insufficiency (EPI) is a medical condition characterized by the pancreas's insufficient production or release of digestive enzymes into the small intestine. These enzymes are essential for the digestion and absorption of nutrients from food. Exocrine pancreatic insufficiency can lead to malnutrition and digestive symptoms, including diarrhea, abdominal pain, bloating, and weight loss.

Sizing and Forecast
The exocrine pancreatic insufficiency market size has grown strongly in recent years. It will grow from $2.41 billion in 2023 to $2.59 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increased awareness and diagnosis, growing prevalence of digestive disorders, aging population and pancreatic function decline, rise in gastrointestinal surgeries..

The exocrine pancreatic insufficiency market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to continued increase in awareness and screening, expanding geriatric population, rising incidence of chronic diseases, improvements in patient access to healthcare, research and development in digestive health.. Major trends in the forecast period include telehealth and digital health solutions, collaborative research initiatives, focus on pediatric epi, regulatory advances and fast-track designations, market expansion in emerging economies, advancements in healthcare infrastructure..

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Segmentation & Regional Insights
The exocrine pancreatic insufficiency market covered in this report is segmented –

1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments
2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), Other Types
3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End Users: Hospitals, Specialty Clinics, Homecare

North America was the largest region in the exocrine pancreatic insufficiency market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=13107&type=smp

Major Driver Impacting Market Growth
The rise in chronic diseases is expected to propel the growth of the exocrine pancreatic insufficiency market going forward. Chronic diseases are long-term medical conditions that persist over an extended period, typically three months or more. The prolonged presence of the underlying disease can also increase the likelihood of developing secondary complications like exocrine pancreatic insufficiency, which fuels the better management of chronic conditions through medical interventions and therapies and can lead to longer life spans for individuals with these conditions. For instance, in January 2023, according to a report published by the National Library of Medicine, a US-based agency, the number of individuals aged 50 years and older having one or more chronic illnesses and is projected to rise by 99.5%, reaching 142.66 million by 2050, up from 71.522 million in 2020 in the United States. Therefore, the rise in chronic diseases will drive the growth of the exocrine pancreatic insufficiency market.

Key Industry Players
Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic plc, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan plc, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma Plc, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc, Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics

The exocrine pancreatic insufficiency market report table of contents includes:

1. Executive Summary
2. Exocrine Pancreatic Insufficiency Market Characteristics
3. Exocrine Pancreatic Insufficiency Market Trends And Strategies
4. Exocrine Pancreatic Insufficiency Market – Macro Economic Scenario
5. Global Exocrine Pancreatic Insufficiency Market Size and Growth

.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model